HBM Healthcare Investments today announced the closing of a new equity investment of EUR 20 million
in two tranches into the privately held and Switzerland based Amicus SA.
The financing willallow Amicus to accelerate the growth of its pharmaceutical business in Central and Eastern
Europe (CEE).
Amicus is a revenue generating company and was established by the former founders ofPharmaSwiss SA, in which HBM Healthcare Investments was a significant shareholder from 2007 until 2011 when the company was sold.
The company specializes in the distribution of pharmaceutical products, medical equipment and over the counter brands in countries where the originators decide notto maintain a direct presence. Leading healthcare companiessuch as Alcon,Bristol Myers Squibb, Cardinal Health, Expanscience, Grupo Ferrer, General Electric, Genexo, Pfizer, PharmaNutra and Salvat Biotech, amongst others, are represented by Amicus.
For further information, please contact Dr. Andreas Wicki on +41 41 710 75 77, or at
Information on HBM Healthcare Investments Ltd
HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages
an international portfolio of promising companies in the human medicine, biotechnology, medical
technology and diagnostics sectors and related areas. Many of these companies have their lead
products already available on the market or at an advanced stage of development. The portfolio
companies are closely tracked and actively guidedin their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Categories: News


About the Author